Founded in China in 2009, CanSino Biologics Inc. (CanSinoBIO) is an industry-leading biopharmaceutical company, dedicated to providing solutions for the prevention and treatment of infectious diseases globally, through research & development, manufacturing and commercialization of innovative high-quality and affordable vaccine products for human use.
CanSinoBIO has been listed on the Main Board of Hong Kong Exchanges and Clearing Limited (HKEX: 6185.HK) and on the Sci-Tech Innovation Board of the Shanghai Stock Exchange (STAR Market, SSE: 688185), making it the first "A+H" dual-listed vaccine company in China. Currently, our launched products include Menhycia® [Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197)], Menphecia® [Groups A and C Meningococcal Polysaccharide Conjugate Vaccine (CRM197)], Convidecia Air® [Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) for Inhalation], Convidecia® [Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)], and Ad5-EBOV [the recombinant Ebola virus vaccine]. At present, the Company is developing and conducting clinical trials of several products including first-in-class vaccines in China and globally innovative vaccines. CanSinoBIO has developed five key platform technologies, including Adenovirus-based viral vector technology, Synthetic biotechnology, Protein structure design and VLP assembly, mRNA and LNP technology as well as Formulation and drug delivery technology. In addition, the Company owns core intellectual property rights and proprietary technologies related to vaccine products. CanSinoBIO has established a rich portfolio of a pipeline products preventing more than ten diseases, including meningitis, pneumonia, pertussis, diphtheria, tetanus, COVID-19, tuberculosis, shingles, Ebola virus disease etc., and is participating in innovative R&D collaboration with multiple research institutions across the world. We have constructed large-scale manufacturing bases in Tianjin and Shanghai, with a floor area of over 100,000 square meters. Both have been designed and constructed, and are operating in accordance with international standards to manufacture multiple novel vaccines. In addition, local fill-and-finish production lines have been set up in Mexico, Pakistan, and Malaysia to establish joint manufacturing. Our well-established marketing and supply system covering Asia, Latin America, Africa, and other regions ensures the rapid distribution of vaccine products worldwide. As a leading enterprise in R&D of innovative vaccine, we are committed to the guard of global public health through the fulfillment of our social and international responsibilities, and the development and supply of high-quality vaccine products, contributing to the global public health programs.
With 30+ years of experience in biotechnology R&D, Dr. Yu is responsible for overseeing strategic development, overall operations and management, and major decision-making.
With 30+ years of operations and management experience in biotechnology, Dr. Chao is responsible for daily operations and management as well as strategic development.
With 20+ years of experience in biotechnology R&D, Dr. Zhu is responsible for leading innovative R&D of vaccines.
With 20+ years of experience in commercial operations, investment, and financing management in the pharmaceutical industry, Ms. Wang is responsible for overall commercial operations.
Dr. George Siber is an infectious disease trained physician with 40 years' experience in developing vaccines and antibody products. Dr. George Siber was an Associate Professor of Dana Farber Cancer Institute at Harvard Medical School and Director of the Massachusetts Public Health Biologic Laboratories. Currently, he is an Adjunct Professor of Medicine at Johns Hopkins Medical School. Dr. Siber served as Executive Vice President and Chief Scientific Officer of Wyeth Vaccines (Pfizer) 1996-2007, leading the development and approval of multiple childhood vaccines including Prevenar 7 and 13. Currently, Dr. Siber is a Co-founder and Board Member of Affinivax and a Board Member of Genocea Biosciences and serves on multiple Scientific Advisory Boards including AdVaccine, Everest, Clover, ILiAD, Valneva, Vaxart and Vaxxinity. Dr. Siber has received multiple awards including the Albert Sabin Gold Medal in vaccinology in 2016.
Dr. Luis Barreto is the President of Dr. Luis Barreto & Associates. Dr. Barreto is a member of the International Advisory Board of the McMaster/Maastricht/Manipal Global Health Program, a member of the Scientific Advisory Board for the Human Health Therapeutics Group of the National Research Council (NRC), Canada, a Senior Scientifc Advisor to Inventprise/InventVac U.S./Canada. Dr. Barreto was formerly Vice-President of Clinical, Medical and Regulatory Affairs, Vice-President of Immunization and Science Policy, and a member of the Senior Management Team at Sanofi Pasteur Canada, as well as a member of its Global Public Policy group. He spent more than 23 years in research and development, leading Phase I-IV clinical trials, licensing and launching vaccines globally. Dr. Barreto has been/is on many volunteer boards of directors, including VIDO-InterVAC (Chair), Research Canada, March of Dimes. He has been/is on many advisory review panels for the Tri Council (CIHR, NSERC and CFI) with the government of Canada and Not for Profit organisations. He has also been member of two panels of the Council of Canadian Academies, Canada.
Prof. Dr. Pierre Van Damme obtained his PhD in epidemiology and public health in 1994. He was for more than 35 years active in vaccine, clinical trial and infectious disease research. Since 2000, he is full professor in Vaccinology at the University of Antwerp, Faculty of Medicine and Health Sciences. Dr. Van Damme is the founder and director of the Centre for the Evaluation of Vaccination (CEV, University of Antwerp), a World Health Organization (WHO) Collaborating Centre for the control and prevention of infectious diseases in European region. Dr. Van Damme has been for more than 25 years a regular advisor for national and international organizations, including the National Immunization Technical Advisory Group, and the WHO. He has been appointed as chairman of the European Technical Advisory Group of Experts on communicable diseases and vaccines for the WHO European Region (ETAGE) (2005-2015).
Prof. David Salisbury was Director of Immunisation at the Department of Health and has chaired the Strategic Advisory Group of Experts on immunisation for the World Health Organisation (WHO). He has led the introduction of a large number of new immunisation programmes and vaccines. The UK immunisation programme is one of the foremost in the world and its excellence is recognised in both developed and developing countries. He has demonstrated that the successful immunisation programmes require the collaboration of science, policy development, strategy and implementation, and whose impact has been the saving of thousands of lives. He is the Chair of the Jenner Vaccine Foundation and is a Board Trustee of the Sabin Vaccine Institute. Prof. David Salisbury is also Chair of the WHO Global Commission for Certification of Poliomyelitis Eradication.
Prof. Jingren Zhang is the professor of Medical School in Tsinghua university, mainly focusing on the molecular mechanism of acute pneumonia and related diseases. Prof. Zhang obtained his doctorate in microbiology from the University of Texas Health Science Center-Houston in 1997. During 1998 to 2000, he worked as a postdoctoral fellow in the department of infectious diseases at St. Jude Children's Research Hospital. Prof. Zhang worked in the China Agricultural University, associate professor from Albany Medical College, US and a visiting professor by institute of microbiology, Chinese Academy of Sciences.
In the process of building an excellent reputation, CanSinoBIO always adheres to the belief of "compliance with the law".
Integrity, ethics and compliance are key to the sustainable development and success of CanSinoBIO today and in the future to maintain public trust, respect and recognition.
津公网安备12011602300399
